Kintor Pharmaceutical Collaborates with Fosun Pharma to commercialize Proxalutamide in Africa

AFRICA – Kintor Pharmaceutical Limited has announced that it has entered into a licensing agreement with Shanghai Fosun Pharmaceutical Development on the commercialization of proxalutamide for the treatment of COVID-19 in 28 African countries. Kintor and Fosun Pharma Development will collaborate on the emergency use authorization applications, promotion, and sales of proxalutamide for the treatment of COVID-19 indication. Proxalutamide is a new-generation androgen receptor (AR) antagonist. Since the outbreak of the COVID-19 pandemic in early 2020, Kintor Pharmaceutical has made rapid progress on the study on proxalutamide as a potential…

Read More